Immunotherapy — represented by immune checkpoint blockade using antibodies against cytotoxic T lymphocyte–associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death-ligand 1 (PD-L1) — has achieved remarkable clinical success in cancer therapy (1, 2). Here, PDCD1 is linked to cancer.